Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NLSP - NLS Pharmaceutics Ltd


IEX Last Trade
0.1513
0.000   0.132%

Share volume: 374,178
Last Updated: Fri 30 Aug 2024 09:24:11 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$0.15
0.00
0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-14.90%
1 Month
-38.39%
3 Months
-10.29%
6 Months
-61.27%
1 Year
-85.09%
2 Year
-69.57%
Key data
Stock price
$0.15
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.11 - $1.21
52 WEEK CHANGE
-$0.87
MARKET CAP 
5.319 M
YIELD 
N/A
SHARES OUTSTANDING 
35.672 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$387,102
AVERAGE 30 VOLUME 
$595,212
Company detail
CEO:
Region: US
Website: nlspharma.com
Employees: 7
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

mission & values to serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. we value partnership and integrity, we are ethical and responsible and show respect and compassion for our patients. r&d strategy the successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. r&d is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. the advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. our innovative r&d is centered on patients’ needs and delivering affordable, safe and effective solutions. not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & developm

Recent news